Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
N274909-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $190.90 | |
N274909-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $292.90 | |
N274909-25mg | 25mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $658.90 | |
N274909-50mg | 50mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,185.90 |
Potent and selective CXCR3 antagonist
Specifications & Purity | Moligand™, ≥96% |
---|---|
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | ANTAGONIST |
Mechanism of action | Antagonist of CXCR3 |
Note | Refer to SDS for further information Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details. |
Product Description |
(±)-NBI 74330 is an effective and selective CXCR3 antagonist.
|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
IUPAC Name | N-[1-[3-(4-ethoxyphenyl)-4-oxopyrido[2,3-d]pyrimidin-2-yl]ethyl]-2-[4-fluoro-3-(trifluoromethyl)phenyl]-N-(pyridin-3-ylmethyl)acetamide |
---|---|
INCHI | InChI=1S/C32H27F4N5O3/c1-3-44-24-11-9-23(10-12-24)41-30(39-29-25(31(41)43)7-5-15-38-29)20(2)40(19-22-6-4-14-37-18-22)28(42)17-21-8-13-27(33)26(16-21)32(34,35)36/h4-16,18,20H,3,17,19H2,1-2H3 |
InChi Key | XMRGQUDUVGRCBS-UHFFFAOYSA-N |
Canonical SMILES | CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2C(C)N(CC4=CN=CC=C4)C(=O)CC5=CC(=C(C=C5)F)C(F)(F)F |
Isomeric SMILES | CCOC1=CC=C(C=C1)N2C(=O)C3=C(N=CC=C3)N=C2C(C)N(CC4=CN=CC=C4)C(=O)CC5=CC(=C(C=C5)F)C(F)(F)F |
PubChem CID | 10167713 |
Molecular Weight | 605.58 |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
B2421646 | Certificate of Analysis | Dec 09, 2024 | N274909 |
B2421647 | Certificate of Analysis | Dec 09, 2024 | N274909 |
B2421655 | Certificate of Analysis | Dec 09, 2024 | N274909 |
B2421658 | Certificate of Analysis | Dec 09, 2024 | N274909 |
B2421648 | Certificate of Analysis | Jan 11, 2024 | N274909 |
B2421653 | Certificate of Analysis | Jan 11, 2024 | N274909 |
B2421656 | Certificate of Analysis | Jan 11, 2024 | N274909 |
B2421657 | Certificate of Analysis | Jan 11, 2024 | N274909 |
Solubility | Soluble in DMSO to 50 mM |
---|
1. Heise CE, Pahuja A, Hudson SC, Mistry MS, Putnam AL, Gross MM, Gottlieb PA, Wade WS, Kiankarimi M, Schwarz D et al.. (2005) Pharmacological characterization of CXC chemokine receptor 3 ligands and a small molecule antagonist.. J Pharmacol Exp Ther, 313 (3): (1263-71). [PMID:15761110] [10.1021/op500134e] |